Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
|
VOR BIOPHARMA INC. (Name of Issuer) |
Common Stock, par value $.0001 per share (Title of Class of Securities) |
929033108 (CUSIP Number) |
Frank Huang, Manager 101 Mission Street, Suite 1000, San Francisco, CA, 94105 (415) 541-0200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
10/02/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 929033108 |
| 1 |
Name of reporting person
Reprogrammed Interchange LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CALIFORNIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,597,308.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
23.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
The number of shares set forth rows 8, 10 and 11 reflect the 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock effected September 18, 2025 (the "Reverse Stock Split").
SCHEDULE 13D
|
| CUSIP No. | 929033108 |
| 1 |
Name of reporting person
Reid Hoffman | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,597,308.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
23.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The number of shares set forth rows 8, 10 and 11 reflect the Reverse Stock Split.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $.0001 per share | |
| (b) | Name of Issuer:
VOR BIOPHARMA INC. | |
| (c) | Address of Issuer's Principal Executive Offices:
100 Cambridgepark Drive, Suite 101, Cambridge,
MASSACHUSETTS
, 02140. | |
Item 1 Comment:
This Amendment No. 4 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto filed with the Securities and Exchange Commission on August 29, 2025, September 9, 2025 and September 12, 2025, respectively (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 4 to Schedule 13D are incorporated by reference into the response to each other item, as applicable. | ||
| Item 3. | Source and Amount of Funds or Other Consideration | |
Not applicable. | ||
| Item 4. | Purpose of Transaction | |
Item 4 of Schedule 13D is hereby amended and supplemented as follows: From September 12, 2025 through October 3, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 15,000 shares on September 12, 2025, at a weighted average per share sale price of $35.0811. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 2. 20,000 shares on September 15, 2025, at a weighted average per share sale price of $32.815. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 3. 22,363 shares on September 16, 2025, at a weighted average per share sale price of $30.8023. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 4. 1,400 shares on October 1, 2025, at a weighted average per share sale price of $39.1925. 5. 32,451 shares on October 2, 2025, at a weighted average per share sale price of $39.828. 6. 7,901 shares on October 3, 2025, at a weighted average per share sale price of $37.832. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 4 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5. | |
| (b) | Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. | |
| (c) | During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions. Each share amount and weighted average per share sale price reflects the Reverse Stock Split. 1. 19,367 shares on August 25, 2025, at a weighted average per share sale price of $42,3256. 2. 14,209 shares on August 26, 2025, at a weighted average per share sale price of $41.6165. 3. 30,582 shares on August 27, 2025, at a weighted average per share sale price of $40.1057. 4. 40,317 shares on August 28, 2025, at a weighted average per share sale price of $40.2307. 5. 27,730 shares on September 3, 2025, at a weighted average per share sale price of $39.9222. 6. 22,650 shares on September 4, 2025, at a weighted average per share sale price of $38.5709. 7. 20,000 shares on September 5, 2025, at a weighted average per share sale price of $39.3639. 8. 23,221 shares on September 8, 2025, at a weighted average per share sale price of $39.7949. 9. 22,461 shares on September 9, 2025, at a weighted average per share sale price of $40,0084. 10.17,500 shares on September 10, 2025, at a weighted average per share sale price of $36.3019. 11.14,240 shares on September 11, 2025, at a weighted average per share sale price of $36.6151. | |
| (d) | Not applicable. | |
| (e) | Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Not applicable. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|